Creative Medical Technology Holdings, Inc. (CELZ) Stock Price & Analysis

Creative Medical Technology Holdings, Inc. (CELZ) rose 0.49% to USD 2.18 as of June 10, 2026 at 09:55 UTC, according to Nexqual real-time market data.

CELZ last closed at USD 2.17; the session ranged USD 2.12–2.22 on volume of 19,347 shares. Market capitalization is $8.06M, with a 52-week range of USD 1.5–6.25 (NCM). Source: Nexqual, June 10, 2026 at 09:55 UTC.

Key Statistics (as of June 10, 2026 at 09:55 UTC)

Technical Analysis (CELZ)

Nexqual's technical model rates CELZ "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 09:55 UTC.

Analyst Ratings (CELZ)

Wall Street analysts rate CELZ "None" based on 1 analysts, with a mean price target of USD 20 (range USD 20–20), per Nexqual as of June 10, 2026 at 09:55 UTC.

Earnings (CELZ)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 09:55 UTC.

Financials & Fundamentals (CELZ)

Source: Nexqual, June 10, 2026 at 09:55 UTC.

Financial Health Score (CELZ)

Nexqual rates Creative Medical Technology Holdings, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 09:55 UTC.

Ownership (CELZ)

Source: Nexqual, June 10, 2026 at 09:55 UTC.

Leadership (CELZ)

Creative Medical Technology Holdings, Inc. is led by Timothy Warbington (age 63), Co-Founder, Chairman, President & CEO, per Nexqual as of June 10, 2026 at 09:55 UTC.

Major Backers & Investors (CELZ)

Notable institutional backers of Creative Medical Technology Holdings, Inc. include Fidelity, Xtx Topco Ltd, Susquehanna International Group, LLP, according to Nexqual as of June 10, 2026 at 09:55 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 09:55 UTC.

From Creative Medical Technology Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-03-20)

Key Strengths & Strategy (as disclosed to the SEC)

• Greenstone's developments were confirmed by an independent, industry-leading research firm.   In October 2022, we announced the development of our AlloStem™ Clinical Cell Line (CELZ-200), a proprietary allogenic cell line which includes a Master Cell Bank and a Drug Master File.
• Fast Track status enables us to benefit from accelerated FDA interactions, rolling Biologics License Application (BLA) submissions, and eligibility for priority review—potentially expediting the path to market and patient access.   In October, 2025 we launched the BioDefense Veterans Initiative, believed to be a first-of-its-kind national program to combat the devastating long-term effects of toxic burn pit exposure among U.S. service members.
• Our patent portfolio is currently composed of seven issued patents and thirty nine pending patent applications filed in the United States with the USPTO as follows:   Issued Patents       Pending Patent Applications       Patent Purchase and License Agreements   Lower Back Pain Patent Purchase.
• The following is a general overview of the laws and regulations pertaining to our business.     FDA Regulation of Stem Cell Treatment and Products   The FDA regulates the manufacture of human stem cell treatments and associated products under the authority of the Public Health Service Act (or PHS Act), and the Federal Food, Drug, and Cosmetic Act (or FDCA).

Partnerships

• The strategic collaboration is expected to extend the progress made on our proprietary hypoimmune iPSC technology, including our iPSC-derived pancreatic islet cells.
• In August 2023, the Company paid CMH $100,000 related to the filing of an IND with the FDA per the terms of the agreement.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 09:55 UTC. This page is informational and not investment advice.